Pedro Berraondo López-rekin lankidetzan egindako argitalpenak (64)

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  2. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  3. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

    Frontiers in Immunology, Vol. 14

  4. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  5. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96

  2. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

  3. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach

    Biomedicines, Vol. 9, Núm. 3, pp. 1-18

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  2. Messenger RNA therapy for rare genetic metabolic diseases

    Gut, Vol. 68, Núm. 7, pp. 1323-1330

  3. Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-a

    Journal of Immunology, Vol. 203, Núm. 3, pp. 696-704

2018

  1. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria

    Human Gene Therapy, Vol. 29, Núm. 4, pp. 480-491

  2. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1326-1334

  3. Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria

    Human Molecular Genetics, Vol. 27, Núm. 21, pp. 3688-3696

  4. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming

    Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654

  5. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2017

  1. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice

    Cell Death and Disease, Vol. 8, Núm. 10

  2. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828